Cargando…

Case Report: Metreleptin Treatment in a Patient With a Novel Mutation for Familial Partial Lipodystrophy Type 3, Presenting With Uncontrolled Diabetes and Insulin Resistance

BACKGROUND: Familial partial lipodystrophy type 3 (FPLD3) is a very rare autosomal dominant genetic disorder which is caused by mutations in the peroxisome proliferator activated receptor gamma (PPARG) gene. It is characterized by a partial loss of adipose tissue leading to subnormal leptin secretio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lambadiari, Vaia, Kountouri, Aikaterini, Maratou, Eirini, Liatis, Stavros, Dimitriadis, George D., Karpe, Fredrik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8217860/ https://www.ncbi.nlm.nih.gov/pubmed/34168618 http://dx.doi.org/10.3389/fendo.2021.684182

Ejemplares similares

Familial Partial Lipodystrophy: Clinical Features, Genetics and Treatment in a Greek Referral Center
por: Kountouri, Aikaterini, et al.
Publicado: (2023)

Regulation of Postabsorptive and Postprandial Glucose Metabolism by Insulin-Dependent and Insulin-Independent Mechanisms: An Integrative Approach
por: Dimitriadis, George D., et al.
Publicado: (2021)

OR17-02 Changes in Hepatokines and Apolipoproteins Are Associated with Metabolic Response to Metreleptin in Partial Lipodystrophy
por: Akinci, Baris, et al.
Publicado: (2020)

Case Report: Metreleptin and SGLT2 Inhibitor Combination Therapy Is Effective for Acquired Incomplete Lipodystrophy
por: Nagayama, Ayako, et al.
Publicado: (2021)

Metreleptin therapy in LMNA-linked lipodystrophies
por: Vatier, Camille, et al.
Publicado: (2015)

Effect of the first and second COVID-19 associated lockdown on the metabolic control of patients with type 2 diabetes in Greece
por: Papachristoforou, Eleftheria, et al.
Publicado: (2023)

Metreleptin and Metformin Use in an Infant With Congenital Generalized Lipodystrophy Secondary to AGPAT2 Mutation
por: Schweisberger, Cintya, et al.
Publicado: (2021)

Bariatric Surgery and Type 1 Diabetes: Unanswered Questions
por: Korakas, Emmanouil, et al.
Publicado: (2020)

SAT676 Severe Recurrent Pancreatitis In A Familial Partial Lipodystrophy Patient On Metreleptin
por: Sargin, Pinar, et al.
Publicado: (2023)

Metreleptin Treatment in Three Patients with Generalized Lipodystrophy
por: Musso, Carla, et al.
Publicado: (2017)

SUN-607 Iron Parameters in Patients with Partial Lipodystrophy and Impact of Metreleptin Therapy
por: Boutros, Sabine, et al.
Publicado: (2020)

Efficacy and Safety of Metreleptin in Patients with Partial Lipodystrophy: Lessons from an Expanded Access Program
por: Ajluni, Nevin, et al.
Publicado: (2016)

New advances in the treatment of generalized lipodystrophy: role of metreleptin
por: Rodriguez, Alexander J, et al.
Publicado: (2015)

Effect of COVID-19-associated lockdown on the metabolic control of patients with type 2 diabetes
por: Psoma, Ourania, et al.
Publicado: (2020)

SAT-081 Advanced Lipoprotein Analysis Demonstrates Atherogenic Lipid Profile in Patients with Lipodystrophy That Improves after Metreleptin Treatment
por: Kinzer, Alexandra, et al.
Publicado: (2019)

Suggestive Evidence for an Antidepressant Effect of Metreleptin Treatment in Patients with Lipodystrophy
por: Vieira, Diana Branco, et al.
Publicado: (2022)

Diabetes and COVID-19; A Bidirectional Interplay
por: Kazakou, Paraskevi, et al.
Publicado: (2022)

Effects of Treatment With Continuous Subcutaneous Insulin Infusion on Arterial Stiffness and Endothelial Glycocalyx Compared to MDI Intensification in Patients With Type 1 Diabetes: Improvement After a Six-Month Pump Treatment
por: Kountouri, Aikaterini, et al.
Publicado: (2021)

Vinegar Consumption Increases Insulin-Stimulated Glucose Uptake by the Forearm Muscle in Humans with Type 2 Diabetes
por: Mitrou, Panayota, et al.
Publicado: (2015)

Risk factors for diabetic foot ulcers in metreleptin naïve patients with lipodystrophy
por: Saydam, O, et al.
Publicado: (2021)

Association of Hypoglycemia with Biomarkers of Oxidative Stress and Antioxidants: An Observational Study
por: Papachristoforou, Eleftheria, et al.
Publicado: (2022)

OR33-02 The Treatment of Partial Lipodystrophy in the Setting of Neutralizing Antibody Against Metreleptin with Leptin Receptor Agonist REGN4461
por: Akinci, Baris, et al.
Publicado: (2020)

Type 1 Diabetes Mellitus in the SARS-CoV-2 Pandemic: Oxidative Stress as a Major Pathophysiological Mechanism Linked to Adverse Clinical Outcomes
por: Kountouri, Aikaterini, et al.
Publicado: (2021)

SUN-057 Familial Partial Lipodystrophy Presenting As Recurrent Acute Pancreatitis- Challenges In Management
por: Aljariri Alhesan, Nour, et al.
Publicado: (2019)

Diagnosis of acquired generalized lipodystrophy in a single patient with T-cell lymphoma and no exposure to Metreleptin
por: Esfandiari, Nazanene H., et al.
Publicado: (2019)

FRI056 Effect Of 48 Hour Of Metreleptin In Humans With Lipodystrophy During Controlled Feeding
por: Bukhari, Khulood M, et al.
Publicado: (2023)

SUN-556 Cardiac Phenotype in Familial Partial Lipodystrophy
por: Eldin, Abdelwahab Jalal, et al.
Publicado: (2020)

Association of Glycemic Indices (Hyperglycemia, Glucose Variability, and Hypoglycemia) with Oxidative Stress and Diabetic Complications
por: Papachristoforou, Eleftheria, et al.
Publicado: (2020)

Metreleptin treatment for congenital generalized lipodystrophy type 4 (CGL4): a case report
por: Takeyari, Shinji, et al.
Publicado: (2019)

Metreleptin Supplementation for Improving Lipid and Glycemic Profiles in Acquired Diabetes Lipodystrophy: A Case Report
por: Nagayama, Ayako, et al.
Publicado: (2019)

Metreleptin Robustly Increases Resting-state Brain Connectivity in Treatment-naïve Female Patients With Lipodystrophy
por: Schlögl, Haiko, et al.
Publicado: (2023)

SAT089 Natural History Of Generalized Lipodystrophy Following Early Vs. Late Metreleptin Treatment
por: Brush, Maiah, et al.
Publicado: (2023)

Effects of Different Antidiabetic Medications on Endothelial Glycocalyx, Myocardial Function, and Vascular Function in Type 2 Diabetic Patients: One Year Follow–Up Study
por: Lambadiari, Vaia, et al.
Publicado: (2019)

Natural history and comorbidities of generalised and partial lipodystrophy syndromes in Spain
por: Fernández-Pombo, Antía, et al.
Publicado: (2023)

Eligibility and Awareness Regarding Metabolic Surgery in Patients With Type 2 Diabetes Mellitus in the Real-World Clinical Setting; Estimate of Possible Diabetes Remission
por: Koliaki, Chrysi, et al.
Publicado: (2020)

Familial Partial Lipodystrophy: A Case Study and Review of Recent Literature
por: Tipu, Ali, et al.
Publicado: (2021)

Targeted Therapeutic Approach in Patients With Familial Partial Lipodystrophy Type 3
por: Cohen, Benjamin, et al.
Publicado: (2021)

The acromegaly lipodystrophy
por: Freda, Pamela U.
Publicado: (2022)

The complicated clinical course in a case of atypical lipodystrophy after development of neutralizing antibody to metreleptin: treatment with setmelanotide
por: Akinci, Baris, et al.
Publicado: (2020)

Challenges in Managing Metabolic Complications in a Patient With Familial Partial Lipodystrophy Type 3
por: Shah, Kajal, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_djc5ljve715vmjfkb7o9118vku